Тrial Access to eBooks and Journals on Emerald Insight

With the support of the Bulgarian Information Consortium we are providing trial access to the Emerald Insight platformfrom Emerald Publishing until 13 May 2026.

Emerald Insight is one of the leading digital platforms for academic content, providing access to peer-reviewed journals, eBooks and other scholarly resources. The platform brings together the content of Emerald Publishing and ICE Publishing and offers enhanced search tools, content recommendations and an improved user interface for discovering research publications.

Journals

Emerald’s portfolio includes 313 scholarly journals covering a wide range of disciplines, including health and social care, public policy and environmental management, management and economics etc. 97% of them have a CiteScore, and 171 titles are ranked in the first quartile (Q1) in Scopus subject categories. In 2024 alone, articles from Emerald journals were downloaded over 53 million times, with authors from 142 countries contributing to the journals.

eBooks

The Emerald eBooks collection includes more than 8,800 titles, with around 485 new titles published each year. The books address a wide range of topics including healthcare, social sciences, business and management, as well as global challenges such as sustainability and public policy.

New platform features

The updated Emerald Insight platform (launched in 2025) includes:

  • access to all Emerald and ICE Publishing content in a single platform
  • enhanced search and navigation features
  • content recommendations and Split View functionality
  • improved accessibility and sustainability features, etc.

Take advantage of these resources for a limited time, until 13 May 2026.

Access to the platform www.emerald.com/insight through the university’s internet network is direct and requires no additional login credentials. For remote access outside Medical University – Sofia, please send us a completed request form with your details.

We look forward to your feedback on the platform through our trial access evaluation survey.

Share